NASDAQ:DMACDiaMedica Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.80 -0.35 (-5.69 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$5.80Now: $5.80▼$6.2250-Day Range$4.46MA: $5.81▼$7.3252-Week Range$1.70Now: $5.80▼$8.80Volume27,100 shsAverage Volume61,883 shsMarket Capitalization$82.01 millionP/E RatioN/ADividend YieldN/ABeta2.86 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingDiaMedica Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.33, DiaMedica Therapeutics has a potential upside of 147.1% from its current price of $5.80.Amount of Analyst CoverageDiaMedica Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesDiaMedica Therapeutics has received 73 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDiaMedica Therapeutics has received 94 “underperform” votes. (Add your “underperform” vote.)Community SentimentDiaMedica Therapeutics has received 56.29% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote “Outperform” if you believe DMAC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DMAC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.60% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 20.68% of the stock of DiaMedica Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for DiaMedica Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -7.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -7.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 9.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.14 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DMAC Previous Symbol CUSIPN/A CIKN/A Webwww.diamedica.com Phone763-312-6755Debt Debt-to-Equity Ratio0.01 Current Ratio15.15 Quick Ratio15.15Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales164.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book9.06Profitability EPS (Most Recent Fiscal Year)($0.89) Net Income$-10,650,000.00 Net MarginsN/A Return on Equity-92.84% Return on Assets-83.19%Miscellaneous Employees9 Outstanding Shares14,139,000Market Cap$82.01 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:DMAC Rates by TradingView Receive DMAC News and Ratings via Email Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions How has DiaMedica Therapeutics' stock been impacted by COVID-19 (Coronavirus)? DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DMAC stock has increased by 45.0% and is now trading at $5.80. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of DiaMedica Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DiaMedica Therapeutics. When is DiaMedica Therapeutics' next earnings date? DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for DiaMedica Therapeutics. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics Inc (NASDAQ:DMAC) issued its earnings results on Wednesday, May, 13th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.09. View DiaMedica Therapeutics' earnings history. What price target have analysts set for DMAC? 3 equities research analysts have issued 1-year price targets for DiaMedica Therapeutics' shares. Their forecasts range from $14.00 to $15.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $14.33 in the next year. This suggests a possible upside of 147.1% from the stock's current price. View analysts' price targets for DiaMedica Therapeutics. Has DiaMedica Therapeutics been receiving favorable news coverage? News headlines about DMAC stock have been trending somewhat positive on Wednesday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DiaMedica Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news about DiaMedica Therapeutics. Are investors shorting DiaMedica Therapeutics? DiaMedica Therapeutics saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 19,600 shares, a decline of 14.0% from the June 15th total of 22,800 shares. Based on an average trading volume of 71,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the company's stock are sold short. View DiaMedica Therapeutics' Current Options Chain. Who are some of DiaMedica Therapeutics' key competitors? Some companies that are related to DiaMedica Therapeutics include Bicycle Therapeutics (BCYC), Rigel Pharmaceuticals (RIGL), Pivot Pharmaceuticals (PVOTF), Seres Therapeutics (MCRB), Avadel Pharmaceuticals (AVDL), Liminal BioSciences (LMNL), Concert Pharmaceuticals (CNCE), Urovant Sciences (UROV), Menlo Therapeutics (MNLO), IDEAYA Biosciences (IDYA), OrganiGram (OGI), Spero Therapeutics (SPRO), Abeona Therapeutics (ABEO), Northwest Biotherapeutics (NWBO) and ProQR Therapeutics (PRQR). View all competitors. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Amarin (AMRN), Oncolytics Biotech (ONCY), vTv Therapeutics (VTVT), Adamis Pharmaceuticals (ADMP), Crispr Therapeutics (CRSP), Seelos Therapeutics (SEEL) and Vaxart (VXRT). Who are DiaMedica Therapeutics' key executives? DiaMedica Therapeutics' management team includes the following people: Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 57)Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49) When did DiaMedica Therapeutics IPO? (DMAC) raised $18 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. What is DiaMedica Therapeutics' stock symbol? DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC." How do I buy shares of DiaMedica Therapeutics? Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is DiaMedica Therapeutics' stock price today? One share of DMAC stock can currently be purchased for approximately $5.80. How big of a company is DiaMedica Therapeutics? DiaMedica Therapeutics has a market capitalization of $82.01 million and generates $500,000.00 in revenue each year. The company earns $-10,650,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. DiaMedica Therapeutics employs 9 workers across the globe. What is DiaMedica Therapeutics' official website? The official website for DiaMedica Therapeutics is www.diamedica.com. How can I contact DiaMedica Therapeutics? DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
